Nobel Prize with Impact on Coeliac Disease Research

AOECS extends our congratulations to the American biologist David Baker for being awarded the Nobel Prize in Chemistry on his work in computational protein design. He shares the Nobel Prize with scientists Demis Hassabis and John M. Jumper from Google DeepMind, who were recognised for advancements in protein structure prediction.

Baker’s research utilises AI-driven computational tools to predict and design protein structures with precision. This technology allows scientists to create novel proteins and enzymes, potentially paving the way for treatments or diagnostic tools specifically targeting harmful gluten proteins, which trigger immune responses in individuals with coeliac disease.

The AOECS affiliate member, the Coeliac Disease Foundation, has supported clinical trial recruitment for Baker’s research in the United States. For the coeliac community, these advancements are particularly significant. Baker’s work has directly contributed to the development of TAK-062, an investigational treatment aimed at improving gluten tolerance in individuals with coeliac disease.

“The work of David Baker, Demis Hassabis, and John Jumper has the potential to redefine what’s possible in therapeutic development,” said Marilyn Geller, CEO of the Celiac Disease Foundation. “Their advancements in protein design open new possibilities for treatments that could significantly improve outcomes for people with celiac disease. We are eager to see how their research will continue to shape the future of medicine.”